A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Adv
Egile Nagusiak: Ni, Qianqian, Zhang, Fuwu, Liu, Yijing, Wang, Zhantong, Yu, Guocan, Liang, Brian, Niu, Gang, Su, Ting, Zhu, Guizhi, Lu, Guangming, Zhang, Longjiang, Chen, Xiaoyuan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Association for the Advancement of Science 2020
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7080439/
https://ncbi.nlm.nih.gov/pubmed/32206706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aaw6071
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak